KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Accounts Payables (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Accounts Payables for 6 consecutive years, with $18.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accounts Payables fell 16.17% year-over-year to $18.1 million, compared with a TTM value of $18.1 million through Dec 2025, down 16.17%, and an annual FY2025 reading of $18.1 million, down 16.17% over the prior year.
  • Accounts Payables was $18.1 million for Q4 2025 at Recursion Pharmaceuticals, up from $13.9 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $25.1 million in Q1 2025 and bottomed at $2.1 million in Q2 2023.
  • Average Accounts Payables over 5 years is $7.8 million, with a median of $4.2 million recorded in 2022.
  • The sharpest move saw Accounts Payables crashed 47.01% in 2024, then skyrocketed 516.59% in 2025.
  • Year by year, Accounts Payables stood at $2.8 million in 2021, then surged by 62.68% to $4.6 million in 2022, then dropped by 13.8% to $4.0 million in 2023, then soared by 446.75% to $21.6 million in 2024, then fell by 16.17% to $18.1 million in 2025.
  • Business Quant data shows Accounts Payables for RXRX at $18.1 million in Q4 2025, $13.9 million in Q3 2025, and $19.3 million in Q2 2025.